Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Major depressive disorder (MDD) is a common chronic and ... which limits the number of sessions and the type of treatment that can be provided, it has become important for clinicians to identify ...

Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

(NASDAQ:NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD). This would be ...

MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed ...

Imade Nibokun, 37, has had depressive episodes since childhood. But she reached a crisis point in December 2012 as a graduate student at the University of Southern California. “It had gotten ...

Major depressive disorder (MDD) is a leading cause of disability worldwide and unfortunately no treatment without side effects is available. Previous reports have found unbalanced glutamate-glutamine ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, according to a study published online Dec. 30 in JAMA Network Open.